Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can newer blood thinners beat aspirin for clot prevention in blood cancer patients?

NCT ID NCT05198960

Disease control Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether direct oral anticoagulants (DOACs) like apixaban or rivaroxaban are better than low-dose aspirin at preventing blood clots in people with JAK2V617F-positive myeloproliferative neoplasms (blood cancers). The study plans to enroll 1308 high-risk patients. The goal is to see if these newer blood thinners reduce the risk of dangerous clots without causing too much bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Apixaban or Rivaroxaban (blood thinners)
What this could lead to
If successful, this could offer a more effective way to prevent dangerous blood clots in people with certain blood cancers, potentially reducing strokes and heart attacks.
What could go wrong
This is a large phase 3 trial, but blood thinners carry a risk of serious bleeding. It is unclear if the benefits will outweigh this risk in this specific patient group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,308 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with diagnosis of PV or ET or PreMF according to WHO or BSCH criteria (bone marrow biopsy not compulsory). * Patients with JAK2V617F mutation (threshold allele burden \> 1%). * Patients considered as "high-risk" patients: 1. based on age (\> 60-year-old) 2. based on thrombotic history (compatible with antithrombotic randomization) but aged ≥ 18-year-old. * Length of time from MPN diagnostic to inclusion will not exceed 12 months. Exclusion Criteria: * Contra-indication to aspirin or DOAC due to allergic situation or recent history of major bleeding. * Formal indication of treatment with aspirin or DOAC (thus precluding randomization). * Inability to give informed consent. * Patients under curatorship/guardianship * Concomitant use of a strong inhibitor or inducer of CYP3A4 (like ruxolitinib). * Chronic liver disease or chronic hepatitis. * Renal insufficiency with creatinine \<30 ml/mn on Cockcroft and Gault Formula * Patient considered at high-risk of bleeding: patients with current or recent major or clinical relevant non major bleeding gastrointestinal or cerebral bleedings * Planned pregnancy within 24 months * No appropriate contraception (estrogen contraception or no contraception) in women of childbearing age or breastfeeding woman * PS\>2 or life expectancy \<12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential thrombocythemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera cellular phase chronic idiopathic myelofibrosis essential thrombocythemia Hemorrhage primary myelofibrosis venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential thrombocythemia High risk patients JAK2 V617F Polycythemia vera Prefibrotic/early primary myelofibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    42 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Bretagne Atlantique Vannes

    RECRUITING

    Vannes, 56017, France

  • CH Le Mans

    NOT_YET_RECRUITING

    Le Mans, 72000, France

  • CH Libourne

    NOT_YET_RECRUITING

    Libourne, 33500, France

  • CH Paul-Brousse (APHP)

    NOT_YET_RECRUITING

    Villejuif, 94800, France

  • CH d'Annecy

    NOT_YET_RECRUITING

    Annecy, 74374, France

  • CH d'Argenteuil

    NOT_YET_RECRUITING

    Argenteuil, 95100, France

  • CH d'Avignon

    RECRUITING

    Avignon, 84000, France

  • CH de Béziers

    NOT_YET_RECRUITING

    Béziers, 34500, France

  • CH de Morlaix

    RECRUITING

    Morlaix, 29600, France

  • CH de Perpignan

    NOT_YET_RECRUITING

    Perpignan, 66000, France

  • CH de Périgueux

    RECRUITING

    Périgueux, 24019, France

  • CH de Rochefort

    NOT_YET_RECRUITING

    Rochefort, 17300, France

  • CH de Roubaix

    RECRUITING

    Roubaix, 59100, France

  • CH de Versailles

    NOT_YET_RECRUITING

    Versailles, 78150, France

  • CH de la Côte Basque Bayonne

    NOT_YET_RECRUITING

    Bayonne, 64100, France

  • CHD Vendée La Roche Sur Yon

    RECRUITING

    La Roche-sur-Yon, 85925, France

  • CHIC de Quimper

    RECRUITING

    Quimper, 29107, France

  • CHR d'Orléans

    RECRUITING

    Orléans, 45100, France

  • CHU Bordeaux

    RECRUITING

    Bordeaux, 33604, France

  • CHU Brest

    RECRUITING

    Brest, 29609, France

  • CHU Grenoble Alpes

    RECRUITING

    Grenoble, 38043, France

  • CHU La Réunion - Site Nord Félix GUYON

    NOT_YET_RECRUITING

    Saint-Denis, 97405, France

  • CHU La Réunion - Site Sud

    NOT_YET_RECRUITING

    Saint-Pierre, 97410, France

  • CHU Le Havre

    NOT_YET_RECRUITING

    Le Havre, 76083, France

  • CHU d'Angers

    RECRUITING

    Angers, 49933, France

  • CHU de Clermont-Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63003, France

  • CHU de Limoges - Hôpital Dupuytren

    RECRUITING

    Limoges, France

  • CHU de Montpellier

    NOT_YET_RECRUITING

    Montpellier, 34295, France

  • CHU de Nancy

    RECRUITING

    Nancy, 54511, France

  • CHU de Nantes - Hôtel-Dieu

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • CHU de Rennes

    NOT_YET_RECRUITING

    Rennes, 35033, France

  • CHU de Tours

    RECRUITING

    Tours, 37044, France

  • Centre Henri Becquerel de Rouen

    RECRUITING

    Rouen, 76038, France

  • Centre Léon Bérard Lyon

    NOT_YET_RECRUITING

    Lyon, 69000, France

  • Clinique Sainte Anne Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, 92210, France

  • Hôpital Cochin (APHP)

    NOT_YET_RECRUITING

    Paris, 75679, France

  • Hôpital Henri Mondor (APHP)

    RECRUITING

    Créteil, 94010, France

  • Hôpital Privé du Confluent Nantes

    NOT_YET_RECRUITING

    Nantes, 44202, France

  • Hôpital St-Louis (APHP)

    RECRUITING

    Paris, 75010, France

  • Hôpital privé Cesson-Sévigné

    NOT_YET_RECRUITING

    Cesson-Sévigné, 35510, France

  • Institut de Cancérologie Lucien Neuwirth St-Priest-en-Jarez

    RECRUITING

    Saint-Priest-en-Jarez, 42271, France

  • Médipôle Hôpital Mutualiste Villeurbanne

    RECRUITING

    Villeurbanne, 69616, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.